Medine.co.uk

Cisatracurium 2mg/Ml Solution For Injection/Infusion

PACKAGE LEAFLET: INFORMATION FOR THE USER

Cisatracurium 2mg/ml solution for injection/infusion

Cisatracurium

Read all of this leaflet carefully before you

are given this medicine.

•    Keep this leaflet. You may need to read it again.

•    If you have any further questions, ask your doctor, nurse or pharmacist.

•    This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours.

•    If any of the side effects get serious, or if you notice any side effects not listed in this leaflet, please tell your doctor, nurse or pharmacist.

The name of your medicine is Cisatracurium

2mg/ml solution for injection/infusion

In the rest of this leaflet Cisatracurium 2mg/ml

solution for injection/infusion is called

Cisatracurium.

In this leaflet:

1.    What Cisatracurium is and what it is used for

2.    Before you are given Cisatracurium

3.    How to use Cisatracurium

4.    Possible side effects

5.    How to store Cisatracurium

6.    Further information

1. What Cisatracurium is and what it is used for

The active substance is cisatracurium besilate, which belongs to a group of medicines called muscle relaxants.

Cisatracurium is used:

•    to relax muscles during operations on adults and children over 1 month of age, including heart surgery

• to help insert a tube into the windpipe (tracheal intubation), if a person needs help to breathe

•    to relax the muscles of adults in intensive care.

Ask your doctor if you would like more explanation about this medicine.

2. Before you are given Cisatracurium Do not use Cisatracurium if you:

•    are allergic (hypersensitive) to the active substance, any other muscle relaxant or any of the other ingredients in Cisatracurium (listed in Section 6)

•    have reacted badly to an anaesthetic before. Do not receive Cisatracurium if any of the above apply to you. If you are not sure, talk to your doctor, nurse or pharmacist before you receive Cisatracurium.

If you are not sure if any of the above applies to you, talk to your doctor or nurse before using Cisatracurium.

Take special care with Cisatracurium

Check with your doctor, nurse or pharmacist before receiving this medicine if:

•    you have muscle weakness, tiredness or difficulty in co-ordinating your movements (myasthenia gravis)

•    you have a neuromuscular disease, such as a muscle wasting disease, paralysis, motor neurone disease or cerebral palsy

•    you have a burn which requires medical treatment.

•    you have ever had an allergic reaction to any muscle relaxant which was given as part of an operation

If you are not sure if any of the above applies to you, talk to your doctor or nurse, before having Cisatracurium.

Using other medicines Please tell your doctor if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.

In particular tell your doctor if you are taking any of the following:

•    anaesthetics (used to reduce sensation and pain during surgical procedures)

•    antibiotics (used to treat infections)

•    medicines for uneven heart beats (anti-arrhythmics)

•    medicines for high blood pressure

•    water tablets (diuretics), such as furusemide

•    medicines for inflammation of the joints, such as chloroquine or d-penicillamine

•    steroids

•    medicines for fits (epilepsy), such as phenytoin or carbamazepine

•    medicines for mental illness, such as lithium, monoamine oxidase inhibitors (MAOIs) or c hl o r promaz i n e (w h i ch can also be used fo r sickness)

•    medicines containing magnesium

•    medicines for Alzheimer's disease (anticholinesterases e.g. donepezil).

Pregnancy and breast-feeding

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask you r docto r for advice before this medicine is given to you.

Driving and using machines

If you are only staying in hospital for the day, your doctor will tell you how long to wait before leaving the hospital or driving a car. It can be dangerous to drive too soon after having an operation.

3. How to use Cisatracurium How your injection is given

You will never be expected to give yourself this medicine. It will always be given to you by a person who is qualified to do so.

Cisatracurium can be given:

•    as a single injection into your vein (intravenous bolus injection)

•    as a co ntinuous i nfusi o n into your vein. This is where the medicine is slowly given to you over a long period of time.

Your doctor will decide the way you will be given the medicine and the dose you will receive. It will depend on:

•    your body weight

•    the amount and duration of muscle relaxation required

•    your expected response to the medicine.

Use in children

Children less than 1 month old should not be given this medicine.

If you are given more Cisatracurium than you should

Cisatracurium will always be given under carefully controlled conditions. However, if you think that you have been given more than you should tell your doctor or nurse immediately.

4. Possible side effects

Like all medicines, Cisatracurium can cause side effects, although not everybody gets them. If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor.

Allergic reactions (affects less than 1 in 10,000 people)

If you have an allergic reaction, tell your doctor or nurse straight away. The signs may include:

•    sudden wheeziness, chest pain or chest tightness

•    swelling of your eyelids, face, lips, mouth or tongue

•    a lumpy skin rash or 'hives' anywhere on your body

•    a collapse.

Talk to your doctor, nurse or pharmacist if you notice any of the following:

Common (affects less than 1 in 10 people)

•    decrease in heart rate

•    decrease in blood pressure.

Uncommon (affects less than 1 in 100 people)

•    a rash or redness of your skin

•    wheezing or coughing.

Very rare (affects less than 1 in 10,000 people)

•    weak or aching muscles.

If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or nurse.

Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard By reporting side effects you can help provide more information on the safety of this medicine

5. How to store Cisatracurium

•    Keep out of the reach and sight of children.

•    Do not use Cisatracurium after the expiry date which is stated on the pack after 'Exp'. The expiry date refers to the last day of that month.

•    Store in a refrigerator (2°C- 8°C). Do not freeze.

•    Store in the original package in order to protect from light.

•    If diluted, store the infusion solution between 2°C and 8°C and use within 24 hours. Any unused infusion solution should be discarded 24 hours after it was prepared.

•    Medicines should not be disposed of via wastewater or household waste. Your doctor or nurse will dispose of any medicine that is no longer required. These measures will help to protect the environment.

6. Further information What Cisatracurium contains

•    The active substance is cisatracurium (as besilate).

•    The other ingredients are benzene sulfonic acid and water for injection.

What Cisatracurium looks like and contents of the pack

Cisatracurium in clear glass ampoule in a box of 5 and box of 1.

Each 10 ml ampoule contains 20 mg of cisatracurium

Each 5 ml ampoule contains 10 mg of cisatracurium

Each 2.5 ml ampoule contains 5 mg of cisatracurium

Not all pack sizes may be marketed.

Marketing Authorisation Holder and Manufacturer

Marketing Authorisation Holder: Noridem Enterprises Ltd., Evagorou & Makariou, Mitsi Building 3, Office 115, 1065 Nicosia, Cyprus.

Manufacturer: DEMO S.A., 21st km National Road Athens-Lamia, 14568 Krioneri, Athens, Greece.

This medicinal product is authorised in the Member States of the EEA under the following names:

UK:    Cisatracurium 2    mg/ml    Solution    for

Injection/Infusion

IE:    Cisatracurium 2    mg/ml    Solution    for

Injection/Infusion

ES:    CISATRACURIO    KERN    PHARMA    2

MG/ML SOLUCION INYECTABLE Y PARAN PERFUSION EFG

EL: CISATRAL 5MG/ML SOL.INJ.INF

DE: Cisatracurium Noridem 2 mg/ ml Injektions-

/Infusionslosung

AT: Cisatracurium Noridem 2 mg/ ml Injektions-

/Infusionslosung

PL: Cisatracurium Noridem

The following information is intended for medical or healthcare professionals only

This product is for single use only. Use only clear and almost colourless up to slightly yellow/greenish yellow coloured solutions. The product should be visually inspected before use, and if the visual appearance has changed or if the container is damaged, the product must be discarded.

Diluted Cisatracurium is physically and chemically stable for at least 24 hours at 5°C and 25°C at concentrations between 0.1 and 1 mg/mL in the following infusion fluids, in or polypropylene containers.

Sodium Chloride (0.9% w/v) Intravenous Infusion.

Glucose (5% w/v) Intravenous Infusion.

Sodium Chloride (0.18% w/v) and Glucose (4% w/v) Intravenous Infusion.

Sodium Chloride (0.45% w/v) and Glucose (2.5% w/v) Intravenous Infusion.

However, since the product contains no antimicrobial preservative, dilution should be carried out immediately prior to use, or failing this be stored as directed under section 6.3.

Cisatracurium has been shown to be compatible with the following commonly used peri-operative drugs, when mixed in conditions simulating administration into a running intravenous infusion via a Y-site injection port: fentanyl citrate and midazolam hydrochloride. Where other drugs are administered through the same indwelling needle or cannula as Cisatracurium, it is recommended that each drug be flushed through with an adequate volume of a suitable intravenous fluid, e.g., Sodium Chloride Intravenous Infusion (0.9% w/v).

As with other drugs administered intravenously, when a small vein is selected as the injection site, Cisatracurium should be flushed through the vein with a suitable intravenous fluid, e.g., sodium chloride intravenous infusion (0.9% w/v).

This leaflet was last approved in 06/2013.

If this leaflet is difficult to see or read please contact the following address for help: Fannin Limited, Fannin House, South County Business Park, Leopardstown, Dublin 18, Ireland Tel +353-1-2907000